Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1

Status

Completed 34Terminated 8Recruiting 6Active not recruiting 6Unknown 4Withdrawn 2Suspended 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Pancreatic Neoplasms 54Biliary Tract Neoplasms 23Nasopharyngeal Carcinoma 22Carcinoma, Non-Small-Cell Lung 22Cholangiocarcinoma 21Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Non-Muscle Invasive Bladder Neoplasms 10Recurrence 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Sarcoma 7Neoplasms 6Hodgkin Disease 6Gallbladder Neoplasms 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma 3

Interventions

Oxaliplatin 6Gemcitabine 6Cisplatin 4durvalumab 3pembrolizumab 2Leucovorin 2Drug Therapy 2130-nm albumin-bound paclitaxel 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1sintilimab 1pertuzumab 1fludarabine 1atezolizumab 1anlotinib 1Trastuzumab 1Standard of Care 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Long-Term Synaptic Depression 1Irinotecan 1Folfox protocol 1Fluorouracil 1Everolimus 1Cyclophosphamide 1Commerce 1Cholangiopancreatography, Endoscopic Retrograde 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Gallbladder Neoplasms × Gemcitabine × Clear all
NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT07025174 2025-06-17

SAIB

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06214572 2025-04-11

RUGB

Tata Memorial Centre

Phase 2/3 Recruiting
249 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT06852287 2025-02-28

GOLD-HAIC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04183712 2024-10-16

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
102 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡